UNSPSC 51292929: Trimipramine maleate

This classification denotes a tricyclic antidepressant with the molecular formula C20H26N2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 269K6498LD, chemically known as 5,6-dihydro-n-(3-(dimethylamino)propyl)-11h-dibenz(b,e)azepine but more generally known as trimipramine maleate, which bears US NIH Compound Identifier 3696. European Medicines Agency schedules Trimipramine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04977MIG.

Most nations, for tariff and trade purposes, schedule trimipramine maleate under HS 29339930 and SITC 51577. As of Q4 2014, TRIMIPRAMINE MALEATE remains US FDA's Preferred Term for this commodity. Trimipramine maleate bears US NLM identifiers UMLS ID C0728956 and NCI Concept Code C47773. SMILES: CC(CN1C2CCCCC2CCC3C1CCCC3)CN(C)C.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51292929 Trimipramine maleate is a Commodity code that nominally identifies a specific tricyclic antidepressant pharmaceutical. However, recent state and local solicitations tagged under this code do not reflect procurement of trimipramine maleate itself; instead, they document buying of naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals with various NDCs and dosage forms, and direct-to-manufacturer prescription program capabilities. The code appears to serve as a catch-all pharmaceutical taxonomy entry rather than a specific product line. State and local issuing bodies pursuing pharmaceutical procurement—including county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local governments across multiple jurisdictions including Oregon)—use this code to solicit diverse pharmaceutical products and related services. The work includes routine supply of controlled and OTC medications, competitive bidding for health initiative support, and exploratory market outreach for alternative pharmacy benefit models.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: date anomaly in source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting models outside traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP on January 20, 2026, with proposals due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with contract awards effective July 1, 2026 and a weighted evaluation favoring price competitiveness at 75 percent. The code shows fragmented activity across health-focused state and local buyers with no identifiable repeat solicitation pattern beyond these three.